Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR017 in Relapsed or Refractory CLL or SLL
NCT03331198Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Nov 2017
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Celgene Corporation. Started Nov 2017; status: active, not recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03331198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331198.